Lamiridosin - EU

Lamiridosin is an oral supplement derived from the Corporation’s “Liver Health” formulation and is being prepared for worldwide market launches in late 2010 and early 2011. Preclinical research and observational studies support ongoing research and development as a supplement to existing therapies for populations with chronic liver maladies. Clinical trials with Lamiridosin are planned for the first half of 2010.